# A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

> **NCT06586216** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 16 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** PF-07817883

## Key facts

- **NCT ID:** NCT06586216
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-10
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06586216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06586216, "A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06586216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*